2024-09-18 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Analysis:**

**1.  Performance vs S&P 500 (VOO):** 

*   ABT's cumulative return of 47.16% lags behind the S&P 500 (VOO) at 89.02%.
*   The relative divergence stands at -41.86%, indicating that ABT has underperformed VOO by over 40%. However, this position is within the historical range, representing a 21.22% relative position within its historical performance.

**2. Recent Price Action:**

*   ABT's closing price stands at 117.63.
*   5-day moving average: 116.91
*   20-day moving average: 114.03
*   60-day moving average: 108.48

This suggests a short-term upward trend, with the price trading above all three moving averages.

**3. Technical Indicators:**

*   **RSI (73.23):** The RSI is currently in the overbought territory, suggesting potential for a short-term correction.
*   **PPO (0.11):** The PPO is positive, indicating a bullish momentum.
*   **Delta_Previous_Relative_Divergence (6.06):**  This indicates a short-term upward trend, suggesting potential for further price gains.
*   **Expected Return (25.08%):**  This represents the potential maximum 5-year return on an investment in ABT.

**4.  Recent Earnings and Outlook:**

| Date        | EPS     | Revenue        |
| ----------- | ------- | --------------- |
| 2024-07-31 | 0.74    | 10.38 B$       |
| 2024-05-02 | 0.7     | 9.96 B$       |
| 2023-11-01 | 0.82    | 10.14 B$       |
| 2023-08-03 | 0.79    | 9.98 B$       |
| 2024-07-31 | 0.79    | 9.98 B$       |

*   The most recent earnings report shows an EPS of 0.74, exceeding analyst expectations. 
*   Revenue came in at 10.38 B$, indicating stable performance.
*   The company's diversified business model and strong market position have contributed to its consistent performance.

**Overall Analysis:**

Abbott Laboratories (ABT) is a large-cap healthcare company with a solid track record of growth and profitability. The company is currently trading near its 52-week high, suggesting a strong bullish sentiment. While recent performance has lagged behind the S&P 500, technical indicators suggest a short-term upward trend.  Its diversified product portfolio and strong brand recognition position it well for continued growth in the future. 

However, the RSI entering overbought territory suggests caution. Investors should monitor price action closely for any signs of a pullback. 
